Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for chronic, recurrent, or antibiotic-refractory pouchitis
2020-002695-12Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in pouchitis, sponsored by Amsterdam University Medical Center. Primary endpoint: Clinical relevant remission at 8 weeks. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
pouchitis
Beyond the preview
Go deeper on 2020-002695-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002695-12.